This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Acute Hepatic Porphyria
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
-
Clinical Trial Site, Birmingham, Alabama, United States, 35233
Clinical Trial Site, Gilbert, Arizona, United States, 85234
Clinical Trial Site, San Francisco, California, United States, 90074
Clinical Trial Site, Baltimore, Maryland, United States, 21205
Clinical Trial Site, Boston, Massachusetts, United States, 02114
Clinical Trial Site, Minneapolis, Minnesota, United States, 55455
Clinical Trial Site, New York, New York, United States, 10029
Clinical Trial Site, Winston-Salem, North Carolina, United States, 27157
Clinical Trial Site, Oklahoma City, Oklahoma, United States, 73120
Clinical Trial Site, Philadelphia, Pennsylvania, United States, 19107
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Alnylam Pharmaceuticals,
Medical Director, STUDY_DIRECTOR, Alnylam Pharmaceuticals
2027-04-01